Summary The metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (>100-fold differences in mean values, P <0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response (Andrews et al., 1987) . The contribution of these mechanisms to clinical resistance is not known.
The use of platinum containing drugs has increased the response rates seen in patients with epithelial ovarian cancer. Unfortunately these responses are followed by only a modest increase in survival. This anomoly has been ascribed to the development of resistance to these agents. This resistance is manifested by a reduction in response rates upon relapse. Several mechanisms of resistance have been suggested by in vitro observations. These include alterations in drug transport, glutathione, and glutathione S-transferase levels (Teicher et al., 1987) , levels and changes in DNA-Pt adduct repair (Behrens et al., 1987) , and elevated metallothionein (Andrews et al., 1987) . The contribution of these mechanisms to clinical resistance is not known.
The metallothioneins are a range of low molecular weight (6-7 kD) proteins involved in zinc homeostasis and heavy metal detoxification (Karin & Richards, 1984) . The proteins are rich in sulphydryl groups and are therefore excellent candidates for attacks by electrophiles (such as the platinum drugs). Platinum has been shown to be bound to the metallothionein fraction isolated from cells treated with cisplatin (Endresen et al., 1984) . Metallothionein levels have also been associated with resistance to some alkylating agents, although the proposed mechanism advances a role for these proteins as cofactors or regulatory elements in the repair process, rather than as direct chemical scavengers (Kaina et al., 1990) .
There remains uncertainty as to whether data describing mechanisms of resistance in vitro is relevant to human tumours. This work describes the investigation of metallothionein levels in tumour samples obtained either before chemotherapy (initial debulking) or following combination chemotherapy (second look laparotomy). The study was designed to determine whether any gross change in metallothionein levels occurred following chemotherapy. Metal Age  62  72  70  77  62  60  72  52  71  65  80  76  58  65  64  74  51  62  30  56  67  67  68  64  28  74  53  62  83  73  65  44   61   42  55  64  71  60  40  62  66  72  42  59  48  57  59  60   Figo  stage   3  3  3  3  3  3  3   3   2   3  3   3  3   3  3   3  3   3  3  3  3  3  3   3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3 (Zwelling, 1988) . This study compares the metallothionein content of ovarian tumours taken either before or after cytotoxic chemotherapy. The chemotherapy regimens received by the patients involved more than one agent in all but four of the patients. The majority however received a platinum drug (16/18). The response rate for these combinations has previously been reported by our group at 70 + % (Gurney et al., 1990) . In spite of high initial response rate the majority of patients relapse and die from their disease. Further chemotherapy for patients relapsing after initial chemotherapy has been associated with poor results and the overall response rate for such patients is 20% (Ozols, 1985) . This decrease is due to the development of clinical resistance (Nash & Young, 1988) .
Metallothioneins have been implicated in the mechanism of resistance to platinum drugs in vitro (Andrews et al., 1987; Bakka et al., 1981; Endresen et al., 1984) , however the evidence is confficting. Studies on cell lines have proposed both causal (Kelley et al., 1988) and non-causal (Schilder et al., 1990) relationships between metallothionein and resistance to platinum drugs. Direct scavenging of platinum by these proteins was not believed to be the major protective effect in a cisplatinum resistant cell line as only a small proportion (2%) of intracellular platinum was found to be associated with metallothioneins (Andrews et al., 1987) . A cell line made resistant to heavy metals but cross resistant to cisplatinum however showed elevated levels of metallothioneins and bound significant amounts of platinum (17%). This work also demonstrated that drug-resistant ovarian cell lines selected by challenge with cisplatinum did not show elevated metallothionein. Therefore whereas elevated levels of metallothionein may protect against cisplatinum, resistance developed against this agent does not necessarily evoke this mechanism.
The data presented in this paper show that ovarian tumour tissue has elevated levels of metallothioneins when compared to normal ovary (> 100-fold increase in mean levels). This increase is highly significant (P <0.001). A comparison of tumours from patients who had and those who had not received chemotherapy showed no statistically significant difference in metallothionein levels. Similarly, although numbers were relatively small, no difference was found between patients who showed a response to chemotherapy (n = 8) and those with progressive disease (n = 9). Further analysis of these data showed no relationship between metallothionein levels and age, stage, histology or tumour burden.
These data do not support a direct role for metallothioneins in resistance to platinum drugs in ovarian tumours in vivo. An indirect role, such as that proposed in resistance to nitrosoureas (Kaina et al., 1990) cannot, however, be excluded.
It is not known why tumours express such high levels of metallothionein when compared to normal ovaries. The tumour tissue is believed to arise from epithelial cells, whereas the normal ovary contains many cell types (e.g. including epithelium, germ cells and stromal cells etc.) Therefore some of the observed differences may arise due to cell type specific variations in metallothionein expression. However for a difference of this size (100-fold) to occur the tumour cells must either be expressing very high levels of metallothionein or epithelial cells must express considerably more than the other cell types found in normal ovaries. The methodology used in this study cannot give any information on tumour heterogeneity, and the existence of metallothionein-rich sub-populations within the tumour cannot be excluded. The data show, however, that by the time of laparotomy those tumours which have been exposed to cytotoxic chemotherapy (generally with regimens containing platinum) have similar metallothionein levels to tumours taken before any chemotherapy has been given. These tumours show reduced response rates (i.e. resistance) to further therapy.
The metallothionein levels of tumours have been determined in two groups: tumours which have received no chemotherapy and those which have undergone a course of treatment. Unfortunately no information is available as to the changes which may occur in metallothionein levels during therapy. However no statistically significant difference is seen in the metallothionein content of these two groups. However a large decrease in clinical response is observed (70-20%). A sequential study using tumours derived from the same patient is at present ongoing.
It is not known whether the post-chemotherapy tumours used in this work reflect the metallothionein status of any residual surviving tumour cells, or whether the tumour has arisen by reversion of the surviving tumour to a state similar to that seen before chemotherapy. These questions would again be best answered by the study of a disease in which sequential biopsies can be taken during therapy.
In summary these data show that ovarian tumours have elevated levels of metallothioneins compared to normal ovarian tissue. No significant difference is seen in the metallothionein levels of tumours taken before, or after, cytotoxic chemotherapy. These data do not support a role for metallothionein as a major determinant of response in ovarian tumours in vivo. It is interesting to speculate on the role of this overexpression of metallothionein in ovarian tumour development. Experiments to elucidate the nature of this overexpression are at present being carried out.
